Baseline anemia was associated with 3-6 months of treatment increases in hemoglobin, serum creatinine, and 1-year CCr. Baseline RRI correlated significantly with 3-6 months of treatment increases in hemoglobin, serum creatinine, and 1-year CCr. At 3-6 months of treatment, 41 patients completed the QOL assessment, and ESA dose had been increased in 37 (90%). At baseline, erythropoietin resistance index (RRI) was greater than 1.5 in 24 patients (43%), anemia was present in 41 (74%) and 46 patients (84%) had a decreased creatinine clearance (CCr). QOL and hematologic parameters were assessed at baseline and 3-6 months after initiation of treatment. In a prospective, observational study, 55 patients with NDCKD were treated with ESA. Thus, the objective of this study was to evaluate the effect of erythropoiesis-stimulating agent therapy on hematologic parameters in patients with NDCKD, and then assess the impact of these changes on QOL. Little is known about the effect of treatment on quality of life (QOL) in this population. Other studies suggest that erythropoiesis-stimulating agent (ESA) therapy may decrease mortality in patients with NDCKD. You may want to wait for a fixed.The effect of epoetin treatment on hematologic and quality of life measures in patients with non-dialysis dependent chronic kidney disease.Īnemia of chronic disease (ACD) is common in patients with non-dialysis dependent CKD (NDCKD) and is associated with erythropoietin (EPO)-resistant anemia. Download Foxit Reader as a portable/standalone application. – Foxit Advanced PDF Editor v3.04 Portable (2013). Foxit Advanced PDF Editor V3.04 Portable (2013)Īpache pdfbox – pre-Java 1.8 PDF library – not in favor of.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |